Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 


Business Summary
Logo Inovio Pharmaceuticals, Inc.
Inovio Pharmaceuticals, Inc. (Inovio) is a late-stage biotechnology company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company's DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases. It has completed, current or planned clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus (HCV), hepatitis B virus (HBV), human immunodeficiency virus (HIV), Ebola, Middle East Respiratory Syndrome (MERS) and Zika virus. With its immunotherapy platform, as well as with its CELLECTRA electroporation delivery technology, it has a pipeline of pre-clinical and clinical stage products that have generated in vivo immune responses.

Number of employees : 262 people.
Sales per Business
USD (in Million)%USD (in Million)%
DNA Immunotherapies and Vaccines4.11100%7.41100% +80.24%
Sales per region
USD (in Million)%USD (in Million)%
United States4.11100%7.41100% +80.24%
J. Joseph Kim, Dr.512009President, Chief Executive Officer & Director
Peter D. Kies562002Chief Financial Officer
Laurent M. Humeau, Dr.532019Chief Scientific Officer
Kate E. Broderick, Dr.-2007Senior Vice President-Research & Development
Mammen P. Mammen, Dr.562020Senior Vice President-Clinical Development
Stephen Kemmerrer-2007Senior Vice President-Engineering Development
Jacqueline E. Shea, Dr.542019Chief Operating Officer & Executive Vice President
Simon X. Benito752019Chairman
Wendy L. Yarno652017Independent Director
Lota S. Zoth602019Independent Director
Members of the board
Simon X. Benito752019Chairman
J. Joseph Kim, Dr.512009President, Chief Executive Officer & Director
David B. Weiner, Dr.642016Director
Wendy L. Yarno652017Independent Director
Lota S. Zoth602019Independent Director
Ann Calby Miller, Dr.632019Independent Director
Jay P. Shepard612020Independent Director
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 208,306,017 200,489,971 96.2% 0 0.0% 96.2%
Stock B 0 1,091 0 0.0% 1,082 99.2%
SSgA Funds Management, Inc. 8,894,555 4.27%
The Vanguard Group, Inc. 8,684,511 4.17%
Nikko Asset Management Co., Ltd. 5,156,350 2.48%
BlackRock Fund Advisors 4,501,585 2.16%
Wasatch Advisors, Inc. 3,939,018 1.89%
Coatue Management LLC 3,576,923 1.72%
VHCP Management LLC 2,900,000 1.39%
Geode Capital Management LLC 2,524,403 1.21%
J. Joseph Kim 2,152,031 1.03%
Northern Trust Investments, Inc.(Investment Management) 1,903,696 0.91%
GeneOne Life Science, Inc. (A011000) 1,799,8584.02%18,606,878 USD
Company contact information
Inovio Pharmaceuticals, Inc.
660 West Germantown Pike
Suite 110
Plymouth Meeting, PA 19462-1111

Phone : +1.267.440.4200
Fax : +1.267.440.4242
Web : http://www.inovio.com
Sector Other Biotechnology & Medical Research